Daniel C. Javitt

Nathan Kline Institute for Psychiatric Research

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Joshua T. Kantrowitz

Columbia University

Gail Silipo

Nathan Kline Institute for Psychiatric Research

Pamela D. Butler

Nathan Kline Institute for Psychiatric Research

Antı́gona Martı́nez

Nathan Kline Institute for Psychiatric Research

John J. Foxe

Albert Einstein College of Medicine

Pejman Sehatpour

Nathan Kline Institute for Psychiatric Research

Matthew J. Hoptman

New York University

Elisa C. Dias

New York University

Jeffrey A. Lieberman

Columbia University

Cheryl M. Corcoran

Icahn School of Medicine at Mount Sinai

Cooperative Institutions

Nathan Kline Institute for Psychiatric Research

212

Columbia University

211

Columbia University Irving Medical Center

115

New York State Psychiatric Institute

107

New York University

New York Psychoanalytic Society and Institute

Yale University

Harvard University

Albert Einstein College of Medicine

Icahn School of Medicine at Mount Sinai

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

DTI and impulsivity in schizophrenia: a first voxelwise correlational analysis

Neuroreport (2004)

Matthew J. Hoptman Babak A. Ardekani Pamela D. Butler Jay Nierenberg Daniel C. Javitt

Compromised white matter (WM) integrity in inferior frontal WM has been related to impulsivity in men with schizophrenia. However, these relationships may be more widespread. Fractional anisotropy (FA) derived from diffusion tensor imaging of 25 men with schizophrenia was transformed into Talairach space. Correlations between FA and impulsiveness were examined on a voxelwise basis. We found negative correlations between FA and impulsivity in inferior frontal WM, anterior cingulate, caudate, insula, and inferior parietal lobule. Positive correlations were obtained in the left postcentral gyrus, right superior/middle temporal gyrus, and bilateral fusiform gyrus. These areas may comprise a fronto-temporo-limbic circuit that modulates impulsivity. The voxelwise correlation method can serve as a hypothesis-generation method for relating target behaviors to their underlying neural networks.

Inferior parietal lobule

Postcentral gyrus

Middle frontal gyrus

Limbic system

10.1097/00001756-200411150-00007

Cite

Citations (110)

Neural mechanisms of mismatch negativity (MMN) dysfunction in schizophrenia

International Journal of Psychophysiology (2016)

Migyung Lee Matthew J. Hoptman Pejman Sehatpour Péter Lakatos Elisa C. Dias

Transcranial Direct Current Stimulation

Oddball paradigm

Frontal cortex

10.1016/j.ijpsycho.2016.07.123

Cite

Citations (3)

Amplitude of low-frequency oscillations in schizophrenia: A resting state fMRI study

Schizophrenia Research (2009)

Matthew J. Hoptman Xi‐Nian Zuo Pamela D. Butler Daniel C. Javitt Debra D’Angelo

Cuneus

Lingual gyrus

Parahippocampal gyrus

Superior temporal gyrus

Gyrus

Limbic lobe

10.1016/j.schres.2009.09.030

Cite

Citations (451)

The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): The Efficacy of Glutamatergic Agents for Negative Symptoms and Cognitive Impairments

American Journal of Psychiatry (2007)

Robert W. Buchanan Daniel C. Javitt Stephen R. Marder Nina R. Schooler James M. Gold

Patients with schizophrenia frequently present with negative symptoms and cognitive impairments for which no effective treatments are known. Agents that act at the glycine site of the N-methyl-D-aspartic acid (NMDA) glutamatergic receptor have been suggested as promising treatments for moderate to severe negative symptoms and cognitive impairments.The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST) was a 16-week double-blind, double-dummy, parallel group, randomized clinical trial of adjunctive glycine, D-cycloserine, or placebo conducted at four sites in the United States and one site in Israel. The participants were 157 inpatients and outpatients who met DSM-IV criteria for schizophrenia or schizoaffective disorder and retrospective and prospective criteria for moderate to severe negative symptoms without marked positive, depressive, or extrapyramidal symptoms. The primary outcome measures were the average "rate of change" of Scale for the Assessment of Negative Symptoms (SANS) total scores and change in the average cognitive domain z scores.There were no significant differences in change in the SANS total score between glycine and placebo subjects or D-cycloserine and placebo subjects. A prespecified test for the site-by-treatment-by-time interaction was significant in post hoc tests. One site had greater reduction in the SANS total score for patients receiving D-cycloserine relative to patients receiving placebo. A second site had greater reduction in the SANS total score for placebo patients compared with glycine patients. There were no significant differences between glycine and placebo or D-cycloserine and placebo subjects on the average cognition z score.The study results suggest that neither glycine nor D-cycloserine is a generally effective therapeutic option for treating negative symptoms or cognitive impairments.

Extrapyramidal symptoms

10.1176/appi.ajp.2007.06081358

Cite

Citations (403)

Has an important test been overlooked? Closure flexibility in schizophrenia

Schizophrenia Research (2010)

Pamela D. Butler Isaac Schechter Nadine Revheim Gail Silipo Daniel C. Javitt

Closure (psychology)

10.1016/j.schres.2010.01.005

Cite

Citations (3)

The Initial Field Trials of DSM-5: New Blooms and Old Thorns

American Journal of Psychiatry (2013)

Robert Freedman David A. Lewis Robert Michels Daniel S. Pine Susan K. Schultz

Three articles in this issue detail the process and results of reliability tests for proposed DSM-5 diagnoses and cross-diagnosis symptom domains. The editorial highlights the good reliability of borderline personality disorder and relates the questionable reliability of major depressive disorder to its heterogeneity. The editorial is also available in Spanish, Traditional Chinese, and Simplified Chinese.

DSM-5

10.1176/appi.ajp.2012.12091189

Cite

Citations (278)

438. Meta-Regression of Adjunctive Treatment Trials for Cognitive Deficits in Schizophrenia

Biological Psychiatry (2024)

Jayda Melnitsky Shannon Peleg Megan Mayer Tse‐Hwei Choo Daniel C. Javitt

Meta-regression

10.1016/j.biopsych.2024.02.937

Cite

Citations (0)

ERP evidence of hemispheric independence in visual word recognition

Brain and Language (2010)

Dan Nemrodov Yuval Harpaz Daniel C. Javitt Michal Lavidor

Stimulus (psychology)

Right hemisphere

Lexical access

10.1016/j.bandl.2010.04.004

Cite

Citations (15)

Applying Transcranial Magnetic Stimulation (TMS) Over the Dorsal Visual Pathway Induces Schizophrenia-like Disruption of Perceptual Closure

Brain Topography (2016)

Revital Amiaz Dana Vainiger Ari A. Gershon Mark Weiser Michal Lavidor

10.1007/s10548-016-0487-1

Cite

Citations (8)

Translating Glutamate: From Pathophysiology to Treatment

Daniel C. Javitt Darryle D. Schoepp Peter W. Kalivas Nora D. Volkow Carlos A. Zarate

The neurotransmitter glutamate is the primary excitatory neurotransmitter in mammalian brain and is responsible for most corticocortical and corticofugal neurotransmission. Disturbances in glutamatergic function have been implicated in the pathophysiology of several neuropsychiatric disorders—including schizophrenia, drug abuse and addiction, autism, and depression—that were until recently poorly understood. Nevertheless, improvements in basic information regarding these disorders have yet to translate into Food and Drug Administration–approved treatments. Barriers to translation include the need not only for improved compounds but also for improved biomarkers sensitive to both structural and functional target engagement and for improved translational models. Overcoming these barriers will require unique collaborative arrangements between pharma, government, and academia. Here, we review a recent Institute of Medicine–sponsored meeting, highlighting advances in glutamatergic theories of neuropsychiatric illness as well as remaining barriers to treatment development.

Drugs of abuse

Cite

Citations (0)